why choose us

First received: August 01, 2023

Clinical Trial: Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects

Study Status: Completed

Recruit Status: RECRUITING

Condition: Healthy

Study Type: INTERVENTIONAL


Official Title: A Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered DF-003 Following Single (Part 1) and Multiple (Pa

Brief Summary: The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics (PK; drug metabolism) of DF-003 after oral administration of single and multiple ascending doses in healthy subjects.The choice of using healthy subjects is standard in establishing the preliminary safety and PK profile of a drug.DF-003 is a potent small molecule inhibitor of alpha-kinase 1 (ALPK1), which plays an important role in immunity and inflammation.DF-003 can inhibit the immune inflammatory response and has been…

Read more